No­var­tis' Xo­lair suc­ces­sor hit by an­oth­er PhI­II axe, but food al­ler­gy study con­tin­ues

Once thought to be a near shoe-in suc­ces­sor to Xo­lair, No­var­tis’ bi­o­log­ic lige­lizum­ab hit an­oth­er road­block, with an ad­di­tion­al Phase III scrapped, the Swiss Big Phar­ma con­firmed to End­points News.

Af­ter lige­lizum­ab failed to beat Xo­lair in two Phase III tri­als in the fall of 2021, No­var­tis is back with an­oth­er late-stage wind-down. The drug de­vel­op­er ter­mi­nat­ed the 39-pa­tient study PEARL-PRO­VOKE, which in­ves­ti­gat­ed the an­ti­body in pa­tients with chron­ic in­ducible ur­ticaria (CIn­dU), an in­flam­ma­to­ry skin con­di­tion in which itchy welts and/or swelling goes on for more than six weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER